Three smaller companies that offer growth at a reasonable price

Professional investor Richard Penny of the TM CRUX UK Special Situations Fund selects three of his favourite small stocks that offer growth, but are not excessively priced.

The distinction between a “growth” investor and a “value” investor has always been a subject of heated debate. In recent years, the growth style of investment has been winning this debate and as growth stocks have become more popular and the winning fund managers get more money to invest, the prices of growth businesses have reached eye-wateringly high levels. As a result buying these growth shares or the funds that invest in them may not seem appealing, however strong the long-term investment drivers behind them may be. 

However, there is a third way. While growth in revenues or profits relates to what is going on in a business, value is about how much you pay for that growth. It is sometimes possible to buy companies growing or exposed to growth trends in overlooked parts of the stockmarket.

The uncertainty surrounding the UK’s political and economic future recently led to the UK stockmarket trading at a big discount to its peers, with the biggest discounts to be found in the bottom 10% of businesses that make up the so-called “small companies” sector. We highlight three that offer exposure to growth where we believe valuations are not excessive.

Cashing in on university spin-offs

IP Group (LSE: IPO) commercialises university intellectual property (IP). It was once a stockmarket darling, but the last five years have seen a big fall in the share price from 250p to 75p. We have some sympathy with the notion that many of IP Group’s companies were floated too early and that the shares had been a bit overhyped five years ago. IP Group has gone backwards while many investment plays in biotechnology, green energy and digital technologies have advanced strongly. Now, however, we see some good progress in IP Group’s portfolio, notably at Oxford Nanopore Technologies (which specialises in gene sequencing) and Ceres Power (green power) The net asset value (NAV) in June 2019 was 110p. We think that the good news will start to drive the share price of the company higher as the discount to NAV narrows.

Inspired Energy is looking more exciting

Inspired Energy (Aim: INSE) has if anything been a rather unexciting business; it sells energy to small companies. Still, there has been a nice progression of revenues, profits and dividends over several years. We think the company’s prospects look auspicious. It should thrive by selling energy-audit and clean-energy strategies to its captive client base. These green drivers should lead to a stockmarket reassessment and revaluation of the company’s shares.

Money in modifying genes

Twenty years ago the sequencing of the human genome was hailed as a great scientific breakthrough. There are now many new drugs being developed that involve gene editing. 

MaxCyte (Aim: MXCT) makes scientific instruments for modifying genes and counts 20 of the world’s biggest pharmaceutical companies as clients in this novel field. Growth has been robust and has accelerated in recent months. MaxCyte also has deals in place with 60 pharmaceutical drug programmes worth up to $650m. We believe that this figure will grow significantly and that the share price trades at a substantial discount to its US counterparts. 

Recommended

Imperial Brands has an 8.3% yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% yield – but what’s the catch?

Tobacco company Imperial Brands boasts an impressive dividend yield, and the shares look cheap. But investors should beware, says Rupert Hargreaves. H…
20 May 2022
What's behind Sri Lanka’s crippling debt crisis?
Emerging markets

What's behind Sri Lanka’s crippling debt crisis?

Sri Lanka has been hit by a triple whammy of economic shocks and has gone to the IMF for a bailout. It may just be the first domino to fall in a globa…
20 May 2022
Investing in drugmakers: uncommon profits from curing rare diseases
Share tips

Investing in drugmakers: uncommon profits from curing rare diseases

Treatments for medical conditions with only a small number of sufferers can still be very attractive for pharmaceutical companies and investors becaus…
20 May 2022
Share tips of the week – 20 May
Share tips

Share tips of the week – 20 May

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 May 2022

Most Popular

Barry Norris: we’re already in the 1970s. Here’s how to invest
Investment strategy

Barry Norris: we’re already in the 1970s. Here’s how to invest

Merryn talks to Barry Norris of Argonaut capital about the parallels between now and the 1970s; the transition to “green” energy; and the one sector w…
19 May 2022
The ten highest dividend yields in the FTSE 100
Income investing

The ten highest dividend yields in the FTSE 100

Rupert Hargreaves looks at the FTSE 100’s top yielding stocks for income investors to consider.
18 May 2022
Share tips of the week – 20 May
Share tips

Share tips of the week – 20 May

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
20 May 2022